Virginia Governor Terry McAuliffe recognizes Biotherapeutics Inc.

BLACKSBURG, VA: Sept. 10, 2015 – Biotherapeutics business plan has been recognized by an honorable mention by the Velocity Program. The Virginia Velocity Business Plan Competition is a State initiative that recognizes the best business ideas in the State of Virginia. The competition is open to all companies in the bioscience and energy sectors, including those based outside Virginia. During the event, Josep Bassaganya-Riera, President and CEO, presented BioTherapeutic’s latest efforts in developing safer and more effective drugs for immune mediated diseases. Virginia Governor Terry McAuliffe and Secretary of Commerce and Trade Maurice Jones recognized BioTherapeutics with an honorable mention and a $50,000 cash award.

“We thank Governor Terry McAuliffe and Secretary of Commerce Maurice Jones for their recognition of BioTherapeutics efforts. The development of disruptive new therapeutics for Crohn’s Disease holds the promise to ameliorate suffering in millions of people worldwide afflicted by Inflammatory Bowel Disease. Biotherapeutic’s demonstrated track record of combining the power of high performance computing, informatics, and modeling with pre-clinical and clinical research has greatly accelerated the path to cures for a number of widespread and debilitating diseases.” Said Dr. Bassaganya-Riera, President and CEO of BioTherapeutics.

Biotherapeutics has recently launched a $20 million fundraising campaign to allow the Company to initiate human studies for BT-11 by 2016. BT-11 is an orally active small molecule therapeutic developed by Biotherapeutics for Crohn’s disease that shows superior efficacy than current and investigational drugs and a benign safety profile.

About Biotherapeutics Inc.

Biotherapeutics Inc. is a science-based biotech company advancing safer and more effective therapeutics for inflammation and diabetes. BioTherapeutics mission is to develop disruptive drug innovation based on novel regulatory mechanisms. Through focused execution, strong patents and committed leadership, Biotherapeutics leverages a broad and expansible product pipeline, and unique therapeutic targets to treat some of the largest threats to global health with significant market opportunities.

Published by Adria Carbo, Director of Business Development